CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
- Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023
- Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023.